Research Institute of Molecular Pathology (IMP)

The Research Institute of Molecular Pathology (IMP) in Vienna is a basic biomedical research institute largely sponsored by Boehringer Ingelheim. With over 200 scientists from 37 nations working in approximately 15 research groups, the IMP is committed to scientific discovery of fundamental molecular and cellular mechanisms underlying complex biological phenomena. Research areas include cell and molecular biology, neurobiology, disease mechanisms and computational biology. The IMP provides its scientists with the resources and freedom they need to follow their own scientific instincts and ideas.

Together with the Max Perutz Labs,  the Institute of Molecular Biotechnology (IMBA),  the Gregor Mendel Institute (GMI) and several biotech companies, the IMP forms the Vienna Biocenter (VBC). 1400 scientists call the VBC their academic home, making Vienna one of the most dynamic life science hubs in Europe. There are many research areas pursued at the VBC, and special expertise has developed in the fields of RNA research; stem cells, regeneration and development; and chromosome and genome biology. The VBC environment ensures that IMP scientists are embedded into a thriving and stimulating academic environment with a critical mass of cutting-edge peers.

At the IMP, we strongly believe that a supportive and collaborative intellectual culture is essential to attract creative and bold scientists, willing to cross the boundaries of their discipline in pursuit of ground-breaking scientific discoveries.